NKTR-255, a novel polymer-conjugated rhIL-15 with potent antitumor efficacy
Takahiro Miyazaki(Nektar Therapeutics (United States)), Jonathan Zalevsky(Nektar Therapeutics (United States)), Saul Kivimäe(Nektar Therapeutics (United States)), Marlene Hennessy(Nektar Therapeutics (United States)), Murali K. Addepalli(Nektar Therapeutics (United States)), Peiwen Kuo(Nektar Therapeutics (United States)), Jicai Huang(Nektar Therapeutics (United States)), Mekhala Maiti(Nektar Therapeutics (United States)), Joanna Wilczek(Nektar Therapeutics (United States)), Loui Madakamutil(Nektar Therapeutics (United States)), Andrew Moffett(Nektar Therapeutics (United States)), Janet Cetz(Nektar Therapeutics (United States)), Thomas K. H. Chang(University of British Columbia), Palakshi Obalapur, Dawei Sheng(Nektar Therapeutics (United States)), Ping Zhang(Ningbo University), Yinyan Tang(Merck & Co., Inc., Rahway, NJ, USA (United States)), Peter Kirk(Immunocore (United Kingdom)), Rhoneil Pena(Nektar Therapeutics (United States)), Sara Sheibani(Nektar Therapeutics (United States)), Werner Rubas(University of California, San Francisco)
Cited by 55
Related Papers
β-Arrestin–Dependent Endocytosis of Proteinase-Activated Receptor 2 Is Required for Intracellular Targeting of Activated Erk1/2
|The Journal of Cell Biology|2000|816
Enhanced antibody half-life improves in vivo activity
|Nature Biotechnology|2010|654
JNK and Tumor Necrosis Factor-α Mediate Free Fatty Acid-induced Insulin Resistance in 3T3-L1 Adipocytes
|Journal of Biological Chemistry|2005|403